Role of SLC7A11/xCT in Ovarian Cancer-Reference-Cited by-同舟云学术

Role of SLC7A11/xCT in Ovarian Cancer

Published:2024-01-02 Issue:1 Volume:25 Page:587
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Fantone Sonia¹,Piani Federica²,Olivieri Fabiola¹³,Rippo Maria Rita³^ORCID,Sirico Angelo⁴,Di Simone Nicoletta⁵⁶^ORCID,Marzioni Daniela⁷^ORCID,Tossetta Giovanni⁷^ORCID

Affiliation:

1. Scientific Direction, IRCCS INRCA, 60124 Ancona, Italy

2. Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy

3. Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, 60126 Ancona, Italy

4. Obstetrics and Gynecology Unit, Sant’Anna e San Sebastiano Hospital, 81100 Caserta, Italy

5. Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy

6. IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy

7. Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy

Abstract

Ovarian cancer is one of the most dangerous gynecologic cancers worldwide and has a high fatality rate due to diagnosis at an advanced stage of the disease as well as a high recurrence rate due to the occurrence of chemotherapy resistance. In fact, chemoresistance weakens the therapeutic effects, worsening the outcome of this pathology. Solute Carrier Family 7 Member 11 (SLC7A11, also known as xCT) is the functional subunit of the Xc− system, an anionic L-cystine/L-glutamate antiporter expressed on the cell surface. SLC7A11 expression is significantly upregulated in several types of cancers in which it can inhibit ferroptosis and favor cancer cell proliferation, invasion and chemoresistance. SLC7A11 expression is also increased in ovarian cancer tissues, suggesting a possible role of this protein as a therapeutic target. In this review, we provide an overview of the current literature regarding the role of SLC7A11 in ovarian cancer to provide new insights on SLC7A11 modulation and evaluate the potential role of SLC7A11 as a therapeutic target.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

https://www.mdpi.com/1422-0067/25/1/587/pdf

Reference127 articles.

1. Perioperative morbidity and mortality in elderly gynecological oncological patients (≥70 Years) by the American Society of Anesthesiologists physical status classes;Giannice;Ann. Surg. Oncol.,2004

2. Ovarian cancer in the world: Epidemiology and risk factors;Momenimovahed;Int. J. Womens Health,2019

3. Kwon, J.Y., Park, K., Song, J.M., Pyeon, S.Y., Lee, S.H., Chung, Y.S., and Lee, J.M. (2023). Risk Factors and Prognosis of Stroke in Gynecologic Cancer Patients. Cancers, 15.

4. Gao, X., Wang, B., Huang, Y., Wu, M., Li, Y., Li, Y., Zhu, X., and Wu, M. (2023). Role of the Nrf2 Signaling Pathway in Ovarian Aging: Potential Mechanism and Protective Strategies. Int. J. Mol. Sci., 24.

5. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer;Zamwar;Cureus,2022